The primary endpoint - MASH improvement absent fibrosis progression - was observed in 47%, 62%, and 43% of the 2.4, 4.8, and vs
The brand calls it a first-of-its-kind program that integrates GLP-1 medications as part of a larger preventive health program. Its website notes that patients receive personalized microdoses of GLP-1 medication, regular at-home biomarker testing and Nooms digital healthy habits platform to empower people with data, insights, personalized action plans and the motivational support to take control of their long-term wellbeing. Ahead, we break down why microdosing is resonating right now, what problem Noom says its addressing and who may be eligible
Clinicians should consider common differentials (e.g., dietary triggers, small intestinal bacterial overgrowth, irritable bowel syndrome) before attributing new or worsening symptoms to either tirzepatide or histamine intolerance
Right now, it is not clear if people can get this side effect or not
How long before I know if a GLP-1 is working
At InCare, our 9 years of Healthcare experience mean were prepared to address your concerns promptly and compassionately
